Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders


Autoria(s): Fagherazzi, Elen V.; Garcia, Vanessa A.; Maurmann, Natasha; Bervanger, Thielly; Halmenschlager, Luis H.; Busato, Stefano B.; Hallak, Jaime E.; Zuardi, Antonio W.; Crippa, Jose A.; Schroeder, Nadja
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

30/10/2013

30/10/2013

2012

Resumo

Rationale Cannabidiol, the main nonpsychotropic constituent of Cannabis sativa, possesses a large number of pharmacological effects including anticonvulsive, sedative, hypnotic, anxiolytic, antipsychotic, anti-inflammatory, and neuroprotective, as demonstrated in clinical and preclinical studies. Many neurodegenerative disorders involve cognitive deficits, and this has led to interest in whether cannabidiol could be useful in the treatment of memory impairment associated to these diseases. Objectives We used an animal model of cognitive impairment induced by iron overload in order to test the effects of cannabidiol in memory-impaired rats. Methods Rats received vehicle or iron at postnatal days 12-14. At the age of 2 months, they received an acute intraperitoneal injection of vehicle or cannabidiol (5.0 or 10.0 mg/kg) immediately after the training session of the novel object recognition task. In order to investigate the effects of chronic cannabidiol, iron-treated rats received daily intraperitoneal injections of cannabidiol for 14 days. Twenty-four hours after the last injection, they were submitted to object recognition training. Retention tests were performed 24 h after training. Results A single acute injection of cannabidiol at the highest dose was able to recover memory in iron-treated rats. Chronic cannabidiol improved recognition memory in iron-treated rats. Acute or chronic cannabidiol does not affect memory in control rats. Conclusions The present findings provide evidence suggesting the potential use of cannabidiol for the treatment of cognitive decline associated with neurodegenerative disorders. Further studies, including clinical trials, are warranted to determine the usefulness of cannabidiol in humans suffering from neurodegenerative disorders.

National Council for Scientific and Technological Development (CNPq) [305905/2009-0]

National Council for Scientific and Technological Development (CNPq)

National Institute for Translational Medicine (INCTTM)

National Institute for Translational Medicine (INCT-TM)

CNPq

CNPq

FAPERGS

FAPERGS

Identificador

PSYCHOPHARMACOLOGY, NEW YORK, v. 219, n. 4, supl. 1, Part 3, pp. 1133-1140, FEB, 2012

0033-3158

http://www.producao.usp.br/handle/BDPI/36780

10.1007/s00213-011-2449-3

http://dx.doi.org/10.1007/s00213-011-2449-3

Idioma(s)

eng

Publicador

SPRINGER

NEW YORK

Relação

PSYCHOPHARMACOLOGY

Direitos

closedAccess

Copyright SPRINGER

Palavras-Chave #CANNABIDIOL #MEMORY #NEURODEGENERATIVE DISORDERS #NEUROPROTECTION #IRON #PARKINSONS-DISEASE #RECOGNITION MEMORY #OXIDATIVE STRESS #ADULT RATS #IN-VITRO #IRON #CANNABINOIDS #HIPPOCAMPUS #TOXICITY #ALZHEIMERS #NEUROSCIENCES #PHARMACOLOGY & PHARMACY #PSYCHIATRY
Tipo

article

original article

publishedVersion